Roche welcomes and fully supports the European Commission's efforts to simplify and improve the EU rules for medical devices and in vitro diagnostics. We appreciate the opportunity to comment. Our comments on the revision proposal highlights changes that are particularly welcome and those needing clarification to address challenges and to safeguard patient safety and access to innovation. Feedback attached.
FHR
F. Hoffmann-La Roche Ltd
Company · Switzerland · EU Transparency Register 18940431725-51
5
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
5
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #232 by legislative files engaged — a count of participation, not a measure of influence.
5.7
declared lobbying FTE
self-declared
€2M+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Roche is a member of the European Federation of Pharmaceutical Industries and Associations EFPIA, MedTech Europe, Dig…
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Head office
- Basel, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track F. in PolicySpeak: request access →
Work at F. Hoffmann-La Roche Ltd? so we know who speaks for it.
Their record over time
F. Hoffmann-La Roche Ltd filed 5 positions between 11 Jun 2025 and 20 Jul 2026, across 3 of the 326 legislative files tracked here, attaching a full position paper 5 times.
2025 · 2 filed2026 · 3 filed
What they argued
F. Hoffmann-La Roche Ltd welcomes the opportunity to give input on the IVDR/MDR targeted revision. In-vitro diagnostics and medical devices are not only critical products in themselves to diagnose and treat medical conditions. They are also enablers for clinical research and to guide and administer pharmaceutical treatments. Our companys extensive portfolio comprises medical devices, IVDs and pharmaceuticals.
Roche welcomes the European Commission's proposal for the Biotech Act. As one of the world's largest biotech companies, we view this Act as a critical opportunity to restore Europe's competitiveness in the global life sciences landscape.
Roche welcomes the objective of the European Commission's Biotech Act initiative. Europe can regain competitiveness by transforming into an efficient ecosystem that leverages the single market with unified rules, fostering Research & Development for innovative medicines and integrated solutions.
F. Hoffmann-La Roche Ltd (Roche) welcomes the European Commissions Safe Hearts Plan and the initiative to establish a Council Recommendation on cardiovascular (CV) health checks by Q4 2026. Roche endorses the EFPIA and MedTech Europe positions, supporting key elements such as the Know Your Numbers by 35 baseline assessment, the combination of systematic and opportunistic screening (make every contact count), and the…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- MedTech Europe · 3 files in common
- EFPIA · 3 files in common
- Deutsche Sozialversicherung Europavertretung (DSV) · 3 files in common
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) · 3 files in common
Showing 5 of 64.
Is this your organization?
Everything on this page comes from F. Hoffmann-La Roche Ltd’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.